Oral water soluble contrast for malignant bowel obstruction

Syrmis, William; Richard, Russell; Jenkins-Marsh, Sue; Chia, Siew Chin; Good, Phillip

doi:10.1002/14651858.cd012014.pub2

Cited by 17 publications

(10 citation statements)

References 19 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…However, a meta-analysis from the Cochrane Database of Systematic Reviews reported that there is also insufficient evidence from randomized controlled trials (RCTs) to determine the therapeutic effects and safety of OWSC in patients with MBO. 70 But in fact, in this meta-analysis, only 1 study, by Lee et al, 71 met the standard of the research, and there were only 9 cases enrolled; the researchers themselves could not draw conclusions from the study. Research on OWSC in MBO is sparse; the lack of evidence does not mean that OWSC is ineffective but that more research is needed.…”

Section: Promotion Of Emptyingmentioning

confidence: 87%

Medical Management of Inoperable Malignant Bowel Obstruction

et al. 2020

View full text Add to dashboard Cite

Objective: To review medical management of inoperable malignant bowel obstruction. Data Sources: A literature review using PubMed and MEDLINE databases searching malignant bowel obstruction, etiology, types, pathophysiology, medical, antisecretory, anti-inflammatory, antiemetic drugs, analgesics, promotion of emptying, prevention of infection, anticholinergics, somatostatin analogs, gastric antisecretory drugs, prokinetic agents, glucocorticoid, opioid analgesics, antibiotics, enema, and adverse effects. Study Selection and Data Extraction: Randomized or observational studies, cohorts, case reports, or reviews written in English between 1983 and November 2020 were evaluated. Data Synthesis: Malignant bowel obstruction (MBO) commonly occurs in patients with advanced or recurrent malignancies and severely affects the quality of life and survival of patients. Its management remains complex and variable. Medical management is the cornerstone of MBO treatment, with the goal of reducing distressing symptoms and optimizing quality of life. Until now, there has been neither a standard clinical approach nor registered medications to treat patients with inoperable MBO. Relevance to Patient Care and Clinical Practice: This review provides information on the etiology, type and pathophysiology, and medical treatment of MBO and related adverse reactions of the drugs commonly used, which can greatly assist clinicians in making clinical decisions when treating MBO. Conclusions: Published research shows that medical management of MBO mainly consists of antisecretory, anti-inflammatory strategies, controlling vomiting and pain, promoting emptying, preventing infection, and combination therapy. Being knowledgeable about the most current treatment options, the related adverse effects, and the evidence supporting different practices is critical for clinicians to provide individualized medical therapy for MBO patients.

show abstract

Section: Promotion Of Emptyingmentioning

confidence: 87%

Medical Management of Inoperable Malignant Bowel Obstruction

et al. 2020

View full text Add to dashboard Cite

show abstract

“…The use of WSCA is well‐established in SBO for diagnostic, prognostic and therapeutic purposes . The evidence base for use of WSCA has focused on adhesive SBO, although there is some preliminary evidence for a role in malignant bowel obstruction . In particular, trials have demonstrated that use of WSCA provides prognostic information to predict which patients with SBO will not resolve on conservative management , providing the trigger for surgical intervention in this group.…”

Section: Discussionmentioning

confidence: 99%

Current management of small bowel obstruction in the UK: results from the National Audit of Small Bowel Obstruction clinical practice survey

et al. 2018

View full text Add to dashboard Cite

show abstract

“…Radiologic testing, typically including a computed tomography scan, will play a large role in determining if an operation should be considered or only medical therapies will be implemented. While oral water‐soluble contrast may have benefit in the benign setting, there is no evidence that it is of benefit with an MBO . Total parenteral nutrition is controversial and there is no evidence for improved survival or quality of life .…”

Section: Clinical Optionsmentioning

confidence: 99%

Malignant bowel obstruction

Krouse

2019

Journal of Surgical Oncology

View full text Add to dashboard Cite

Malignant bowel obstruction (MBO) is a common problem for patients with advanced malignancy, especially colorectal and ovarian cancers. Symptoms include pain, bloating, nausea and vomiting, and inability to eat. Treatment options consist of a wide range of surgical and nonsurgical interventions (medications, endoscopic, or interventional radiology approaches). Outcomes are variable no matter the strategy, and the optimal approach is often not clear. Greater research is needed to assist decision-making for clinicians treating patients with MBO. K E Y W O R D S bowel, malignant, nonsurgery, obstruction, surgery How to cite this article: Krouse RS. Malignant bowel obstruction.

show abstract

Oral water soluble contrast for malignant bowel obstruction

Cited by 17 publications

References 19 publications

Medical Management of Inoperable Malignant Bowel Obstruction

Medical Management of Inoperable Malignant Bowel Obstruction

Current management of small bowel obstruction in the UK: results from the National Audit of Small Bowel Obstruction clinical practice survey

Malignant bowel obstruction

Contact Info

Product

Resources

About